Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Spero Therapeutics, Inc. (SPRO) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Spero Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1701108.
Total stock buying since 2017: $43,885,930.
Total stock sales since 2017: $17,151,400.
Total stock option exercises since 2017: $345,123.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 310,045 | $251,669 | 0 | $0 |
| 2024 | 0 | $0 | 313,660 | $428,381 | 0 | $0 |
| 2023 | 0 | $0 | 86,839 | $126,202 | 0 | $0 |
| 2022 | 357,050 | $3,574,670 | 1,901,796 | $4,279,041 | 0 | $0 |
| 2021 | 1,098,033 | $18,220,288 | 111,000 | $2,083,881 | 8,000 | $47,200 |
| 2020 | 0 | $0 | 604,753 | $9,794,732 | 39,820 | $234,935 |
| 2018 | 80,000 | $1,000,000 | 10,676 | $187,494 | 10,676 | $62,988 |
| 2017 | 1,506,498 | $21,090,972 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-08 | 0 | $0 | 8,267 | $16,285 | 0 | $0 |
| 2025-02 | 0 | $0 | 301,778 | $235,384 | 0 | $0 |
| 2024-11 | 0 | $0 | 40,596 | $53,007 | 0 | $0 |
| 2024-08 | 0 | $0 | 43,323 | $57,334 | 0 | $0 |
| 2024-02 | 0 | $0 | 229,741 | $318,040 | 0 | $0 |
| 2023-09 | 0 | $0 | 39,496 | $50,159 | 0 | $0 |
| 2023-08 | 0 | $0 | 18,765 | $23,809 | 0 | $0 |
| 2023-02 | 0 | $0 | 28,578 | $52,234 | 0 | $0 |
| 2022-09 | 0 | $0 | 1,901,796 | $4,279,041 | 0 | $0 |
| 2022-04 | 39,727 | $207,970 | 0 | $0 | 0 | $0 |
| 2022-03 | 73,708 | $620,197 | 0 | $0 | 0 | $0 |
| 2022-02 | 59,661 | $564,253 | 0 | $0 | 0 | $0 |
| 2022-01 | 183,954 | $2,182,250 | 0 | $0 | 0 | $0 |
| 2021-12 | 250,493 | $3,862,893 | 8,000 | $116,664 | 8,000 | $47,200 |
| 2021-10 | 150,000 | $2,630,250 | 0 | $0 | 0 | $0 |
| 2021-09 | 205,658 | $3,827,551 | 0 | $0 | 0 | $0 |
| 2021-08 | 491,882 | $7,899,594 | 0 | $0 | 0 | $0 |
| 2021-02 | 0 | $0 | 103,000 | $1,967,217 | 0 | $0 |
| 2020-12 | 0 | $0 | 276,933 | $5,209,287 | 12,000 | $70,800 |
| 2020-11 | 0 | $0 | 309,507 | $4,323,867 | 9,507 | $56,091 |
| 2020-10 | 0 | $0 | 14,492 | $206,999 | 14,492 | $85,502 |
| 2020-09 | 0 | $0 | 774 | $11,029 | 774 | $4,566 |
| 2020-07 | 0 | $0 | 3,047 | $43,550 | 3,047 | $17,976 |
| 2018-07 | 80,000 | $1,000,000 | 10,676 | $187,494 | 10,676 | $62,988 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-28 | Keutzer Timothy (Chief Operating Officer) | Sale | 1,695 | 1.97 | 3,339 |
| 2025-08-28 | Mahadevia Ankit | Sale | 6,572 | 1.97 | 12,946 |
| 2025-02-05 | Rajavelu Esther (CFO & CBO) | Sale | 20,689 | .78 | 16,137 |
| 2025-02-05 | Keutzer Timothy (Chief Operating Officer) | Sale | 56,537 | .78 | 44,098 |
| 2025-02-05 | Shukla Sath (CEO & President) | Sale | 155,333 | .78 | 121,159 |
| 2025-02-05 | Mahadevia Ankit | Sale | 69,219 | .78 | 53,990 |
| 2024-11-08 | Rajavelu Esther (CFO & CBO) | Sale | 17,245 | 1.30 | 22,418 |
| 2024-11-07 | Rajavelu Esther (CFO & CBO) | Sale | 23,351 | 1.31 | 30,589 |
| 2024-08-27 | Keutzer Timothy (Chief Operating Officer) | Sale | 2,213 | 1.35 | 2,987 |
| 2024-08-27 | Shukla Sath (CEO & President) | Sale | 2,757 | 1.35 | 3,721 |
| 2024-08-27 | Mahadevia Ankit | Sale | 5,912 | 1.35 | 7,981 |
| 2024-08-05 | Shukla Sath (CEO and President) | Sale | 17,641 | 1.31 | 23,109 |
| 2024-08-02 | Shukla Sath (CEO and President) | Sale | 14,800 | 1.32 | 19,536 |
| 2024-02-05 | Shukla Sath (CEO and President) | Sale | 45,093 | 1.45 | 65,384 |
| 2024-02-02 | Hamed Kamal (Chief Medical Officer) | Sale | 28,075 | 1.37 | 38,462 |
| 2024-02-02 | Keutzer Timothy (Chief Operating Officer) | Sale | 30,971 | 1.36 | 42,120 |
| 2024-02-02 | Shukla Sath (CEO and President) | Sale | 30,901 | 1.37 | 42,334 |
| 2024-02-02 | Mahadevia Ankit | Sale | 63,795 | 1.37 | 87,399 |
| 2024-02-02 | Joseph Tamara L (Chief Legal Officer) | Sale | 30,906 | 1.37 | 42,341 |
| 2023-09-13 | Hamed Kamal (Chief Medical Officer) | Sale | 39,496 | 1.27 | 50,159 |
| 2023-08-29 | Shukla Sath (CEO and President) | Sale | 4,163 | 1.30 | 5,411 |
| 2023-08-28 | Keutzer Timothy (Chief Development Officer) | Sale | 1,854 | 1.26 | 2,336 |
| 2023-08-28 | Shukla Sath (CEO and President) | Sale | 1,854 | 1.26 | 2,336 |
| 2023-08-28 | Mahadevia Ankit | Sale | 9,040 | 1.26 | 11,390 |
| 2023-08-28 | Joseph Tamara L (Chief Legal Officer) | Sale | 1,854 | 1.26 | 2,336 |
| 2023-02-03 | Mahadevia Ankit (CEO and President) | Sale | 12,286 | 1.81 | 22,237 |
| 2023-02-02 | Keutzer Timothy (Chief Operating Officer) | Sale | 3,394 | 1.86 | 6,312 |
| 2023-02-02 | Shukla Sath (Chief Financial Officer) | Sale | 9,504 | 1.83 | 17,373 |
| 2023-02-02 | Joseph Tamara L (Chief Legal Officer) | Sale | 3,394 | 1.86 | 6,312 |
| 2022-09-22 | Aquilo Capital, L.p. (10% Owner) | Sale | 1,901,796 | 2.25 | 4,279,041 |
| 2022-04-26 | Aquilo Capital, L.p. (10% Owner) | Buy | 39,727 | 5.24 | 207,970 |
| 2022-03-30 | Aquilo Capital, L.p. (10% Owner) | Buy | 50,000 | 8.79 | 439,400 |
| 2022-03-14 | Aquilo Capital, L.p. (10% Owner) | Buy | 23,708 | 7.63 | 180,797 |
| 2022-02-28 | Aquilo Capital, L.p. (10% Owner) | Buy | 44,833 | 9.53 | 427,213 |
| 2022-02-18 | Aquilo Capital, L.p. (10% Owner) | Buy | 14,828 | 9.24 | 137,040 |
| 2022-01-31 | Aquilo Capital, L.p. (10% Owner) | Buy | 125,000 | 11.59 | 1,448,250 |
| 2022-01-24 | Aquilo Capital, L.p. (10% Owner) | Buy | 1,599 | 10.89 | 17,417 |
| 2022-01-18 | Aquilo Capital, L.p. (10% Owner) | Buy | 48,488 | 12.41 | 601,978 |
| 2022-01-10 | Aquilo Capital, L.p. (10% Owner) | Buy | 8,867 | 12.93 | 114,605 |
| 2021-12-31 | Aquilo Capital, L.p. (10% Owner) | Buy | 125,000 | 15.75 | 1,969,000 |
| 2021-12-30 | Aquilo Capital, L.p. (10% Owner) | Buy | 50,000 | 15.77 | 788,600 |
| 2021-12-29 | Aquilo Capital, L.p. (10% Owner) | Buy | 75,493 | 14.64 | 1,105,293 |
| 2021-12-27 | Mahadevia Ankit (CEO and President) | Sale | 8,000 | 14.58 | 116,664 |
| 2021-12-27 | Mahadevia Ankit (CEO and President) | Option Ex | 8,000 | 5.90 | 47,200 |
| 2021-10-29 | Aquilo Capital, L.p. (10% Owner) | Buy | 150,000 | 17.54 | 2,630,250 |
| 2021-09-30 | Aquilo Capital, L.p. (10% Owner) | Buy | 134,543 | 18.65 | 2,509,226 |
| 2021-09-14 | Aquilo Capital, L.p. (10% Owner) | Buy | 2,156 | 18.49 | 39,873 |
| 2021-09-13 | Aquilo Capital, L.p. (10% Owner) | Buy | 44,210 | 18.56 | 820,670 |
| 2021-09-09 | Aquilo Capital, L.p. (10% Owner) | Buy | 24,749 | 18.50 | 457,782 |
| 2021-08-31 | Aquilo Capital, L.p. (10% Owner) | Buy | 48,645 | 18.93 | 920,655 |
| 2021-08-30 | Aquilo Capital, L.p. (10% Owner) | Buy | 44,042 | 17.87 | 786,854 |
| 2021-08-24 | Aquilo Capital, L.p. (10% Owner) | Buy | 40,170 | 16.28 | 653,806 |
| 2021-08-23 | Aquilo Capital, L.p. (10% Owner) | Buy | 137,835 | 16.33 | 2,251,396 |
| 2021-08-20 | Aquilo Capital, L.p. (10% Owner) | Buy | 221,190 | 14.86 | 3,286,883 |
| 2021-02-08 | Aquilo Capital, L.p. (10% Owner) | Sale | 3,000 | 21.74 | 65,214 |
| 2021-02-04 | Aquilo Capital, L.p. (10% Owner) | Sale | 34,144 | 18.99 | 648,257 |
| 2021-02-03 | Aquilo Capital, L.p. (10% Owner) | Sale | 29,354 | 18.98 | 557,109 |
| 2021-02-02 | Aquilo Capital, L.p. (10% Owner) | Sale | 22,841 | 18.99 | 433,773 |
| 2021-02-01 | Aquilo Capital, L.p. (10% Owner) | Sale | 13,661 | 19.24 | 262,864 |
| 2020-12-17 | Aquilo Capital, L.p. (10% Owner) | Sale | 250,000 | 18.81 | 4,703,250 |
| 2020-12-16 | Larkin Cristina (Chief Operating Officer) | Sale | 12,000 | 19.00 | 228,000 |
| 2020-12-16 | Larkin Cristina (Chief Operating Officer) | Option Ex | 12,000 | 5.90 | 70,800 |
| 2020-12-16 | Aquilo Capital, L.p. (10% Owner) | Sale | 14,933 | 18.62 | 278,037 |
| 2020-11-09 | Aquilo Capital, L.p. (10% Owner) | Sale | 125,900 | 13.77 | 1,734,020 |
| 2020-11-06 | Aquilo Capital, L.p. (10% Owner) | Sale | 5,000 | 13.78 | 68,875 |
| 2020-11-05 | Aquilo Capital, L.p. (10% Owner) | Sale | 96,600 | 13.98 | 1,350,371 |
| 2020-11-04 | Mahadevia Ankit (CEO and President) | Sale | 7,370 | 14.43 | 106,334 |
| 2020-11-04 | Mahadevia Ankit (CEO and President) | Option Ex | 7,370 | 5.90 | 43,483 |
| 2020-11-04 | Aquilo Capital, L.p. (10% Owner) | Sale | 72,500 | 14.26 | 1,033,777 |
| 2020-11-03 | Mahadevia Ankit (CEO and President) | Sale | 2,137 | 14.27 | 30,490 |
| 2020-11-03 | Mahadevia Ankit (CEO and President) | Option Ex | 2,137 | 5.90 | 12,608 |
| 2020-10-23 | Mahadevia Ankit (CEO and President) | Sale | 20 | 14.25 | 285 |
| 2020-10-23 | Mahadevia Ankit (CEO and President) | Option Ex | 20 | 5.90 | 118 |
| 2020-10-14 | Mahadevia Ankit (CEO and President) | Sale | 105 | 14.25 | 1,496 |
| 2020-10-14 | Mahadevia Ankit (CEO and President) | Option Ex | 105 | 5.90 | 619 |
| 2020-10-13 | Mahadevia Ankit (CEO and President) | Sale | 14,367 | 14.28 | 205,218 |
| 2020-10-13 | Mahadevia Ankit (CEO and President) | Option Ex | 14,367 | 5.90 | 84,765 |
| 2020-09-08 | Mahadevia Ankit (CEO and President) | Sale | 774 | 14.25 | 11,029 |
| 2020-09-08 | Mahadevia Ankit (CEO and President) | Option Ex | 774 | 5.90 | 4,566 |
| 2020-07-09 | Mahadevia Ankit (CEO and President) | Sale | 2,293 | 14.31 | 32,805 |
| 2020-07-09 | Mahadevia Ankit (CEO and President) | Option Ex | 2,293 | 5.90 | 13,528 |
| 2020-07-07 | Mahadevia Ankit (CEO and President) | Sale | 754 | 14.25 | 10,745 |
| 2020-07-07 | Mahadevia Ankit (CEO and President) | Option Ex | 754 | 5.90 | 4,448 |
| 2018-07-17 | Glaxosmithkline Plc | Buy | 80,000 | 12.50 | 1,000,000 |
| 2018-07-06 | Mahadevia Ankit (See Remarks) | Sale | 1,600 | 17.68 | 28,289 |
| 2018-07-06 | Mahadevia Ankit (See Remarks) | Option Ex | 1,600 | 5.90 | 9,440 |
| 2018-07-05 | Larkin Cristina (Chief Operating Officer) | Sale | 4,000 | 17.50 | 70,000 |
| 2018-07-05 | Larkin Cristina (Chief Operating Officer) | Option Ex | 4,000 | 5.90 | 23,600 |
| 2018-07-05 | Mahadevia Ankit (See Remarks) | Sale | 3,076 | 17.62 | 54,205 |
| 2018-07-05 | Mahadevia Ankit (See Remarks) | Option Ex | 3,076 | 5.90 | 18,148 |
| 2018-07-05 | Sendek Joel (Chief Financial Officer) | Sale | 2,000 | 17.50 | 35,000 |
| 2018-07-05 | Sendek Joel (Chief Financial Officer) | Option Ex | 2,000 | 5.90 | 11,800 |
| 2017-11-06 | Larkin Cristina (Chief Operating Officer) | Buy | 1,500 | 14.00 | 21,000 |
| 2017-11-06 | Goyal Vikas (Director) | Buy | 428,571 | 14.00 | 5,999,994 |
| 2017-11-06 | Sendek Joel (Chief Financial Officer) | Buy | 5,000 | 14.00 | 70,000 |
| 2017-11-06 | Breum Casper (Director) | Buy | 214,285 | 14.00 | 2,999,990 |
| 2017-11-06 | Glaxosmithkline Plc | Buy | 428,571 | 14.00 | 5,999,994 |
| 2017-11-06 | Formela Jean Francois (Director) | Buy | 428,571 | 14.00 | 5,999,994 |
Insider trading activities including stock purchases, stock sales, and option exercises of SPRO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Spero Therapeutics, Inc. (symbol SPRO, CIK number 1701108) see the Securities and Exchange Commission (SEC) website.